These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 20149510)

  • 21. Safety and efficacy of denosumab in giant-cell tumour of bone.
    Kyrgidis A; Toulis K
    Lancet Oncol; 2010 Jun; 11(6):513-4. PubMed ID: 20522379
    [No Abstract]   [Full Text] [Related]  

  • 22. Healing of osteonecrosis of the jaw (ONJ) after discontinuation of denosumab in a patient with bone metastases of colorectal cancer: a case report and hypothesis.
    Ohga N; Yamazaki Y; Tsuboi K; Kitagawa Y
    Quintessence Int; 2015; 46(7):621-6. PubMed ID: 25646168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Denosumab-associated osteonecrosis of the jaw--a case report.
    Vyas S; Hameed S; Murugaraj V
    Dent Update; 2014 Jun; 41(5):449-50. PubMed ID: 25073227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increasing options for the treatment of osteoporosis.
    Khosla S
    N Engl J Med; 2009 Aug; 361(8):818-20. PubMed ID: 19671654
    [No Abstract]   [Full Text] [Related]  

  • 25. Denosumab for bone metastases from breast cancer: a new therapy option?
    Aapro MS
    J Clin Oncol; 2011 May; 29(14):e419-20; author reply e421-4. PubMed ID: 21464408
    [No Abstract]   [Full Text] [Related]  

  • 26. Denosumab (Prolia): A new option in the treatment of osteoporosis.
    Belavic JM
    Nurse Pract; 2011 Jan; 36(1):11-2. PubMed ID: 21173630
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial.
    Miller PD; Wagman RB; Peacock M; Lewiecki EM; Bolognese MA; Weinstein RL; Ding B; San Martin J; McClung MR
    J Clin Endocrinol Metab; 2011 Feb; 96(2):394-402. PubMed ID: 21159841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
    Smith MR; Egerdie B; Hernández Toriz N; Feldman R; Tammela TL; Saad F; Heracek J; Szwedowski M; Ke C; Kupic A; Leder BZ; Goessl C;
    N Engl J Med; 2009 Aug; 361(8):745-55. PubMed ID: 19671656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Root canal therapy for the prevention of osteonecrosis of the jaws: an evidence-based clinical update.
    Kyrgidis A; Arora A; Lyroudia K; Antoniades K
    Aust Endod J; 2010 Dec; 36(3):130-3. PubMed ID: 21140589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Denosumab in postmenopausal women with low bone mineral density.
    Schwartzman J; Yazici Y
    N Engl J Med; 2006 Jun; 354(22):2390-1; author reply 2390-1. PubMed ID: 16738280
    [No Abstract]   [Full Text] [Related]  

  • 31. Denosumab an option for patients with bone metastasis from breast cancer.
    Barton MK
    CA Cancer J Clin; 2011; 61(3):135-6. PubMed ID: 21532096
    [No Abstract]   [Full Text] [Related]  

  • 32. Denosumab (prolia) for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2010 Oct; 52(1349):81-2. PubMed ID: 21045756
    [No Abstract]   [Full Text] [Related]  

  • 33. Denosumab osteonecrosis of the mandible: a new entity? A case report.
    Pichardo SE; Kuypers SC; van Merkesteyn JP
    J Craniomaxillofac Surg; 2013 Jun; 41(4):e65-9. PubMed ID: 23265807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
    Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
    Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Denosumab. Limited efficacy in fracture prevention, too many adverse effects.
    Prescrire Int; 2011 Jun; 20(117):145-8. PubMed ID: 21678700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Denosumab: RANKL inhibition in the management of bone loss.
    Hamdy NA
    Drugs Today (Barc); 2008 Jan; 44(1):7-21. PubMed ID: 18301800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of a surgical treatment of denosumab-related osteonecrosis of the jaws.
    Pichardo SE; van Merkesteyn JP
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Sep; 122(3):272-8. PubMed ID: 27234854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Innovations in the treatment of osteoporosis].
    Tsourdi E; Hofbauer LC
    Dtsch Med Wochenschr; 2011 Dec; 136(48):2458-60. PubMed ID: 22109575
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.